Journal
ONCOLOGY RESEARCH AND TREATMENT
Volume 39, Issue 7-8, Pages 461-463Publisher
KARGER
DOI: 10.1159/000446759
Keywords
AZD9291; Osimertinib; Intracranial; Lung cancer; Response; EGFR mutation; T790M
Categories
Ask authors/readers for more resources
Background: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Case Report: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma. Conclusion: These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed. (C) 2016 S. Karger GmbH, Freiburg
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
